Reviewing Chemed (NYSE:CHE) and Mangoceuticals (NASDAQ:MGRX)

Mangoceuticals (NASDAQ:MGRX) and Chemed (NYSE:CHE) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Mangoceuticals and Chemed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,794.60%	-96.39%	-89.60%
Chemed	10.60%	31.77%	18.90%

Valuation & Earnings

This table compares Mangoceuticals and Chemed”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$315,227.00	32.36	-$20.64 million	($1.01)	-0.47
Chemed	$2.60 billion	2.53	$265.24 million	$19.91	25.27

Chemed has higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Mangoceuticals has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500. Comparatively, Chemed has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Mangoceuticals and Chemed, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1	0	0	0	1.00
Chemed	0	5	1	0	2.17

Chemed has a consensus target price of $530.75, suggesting a potential upside of 5.49%. Given Chemed’s stronger consensus rating and higher possible upside, analysts plainly believe Chemed is more favorable than Mangoceuticals.

Insider & Institutional Ownership

56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 95.8% of Chemed shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Comparatively, 3.3% of Chemed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Chemed beats Mangoceuticals on 11 of the 14 factors compared between the two stocks.

About Mangoceuticals

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.